Analysis report China's human rabies vaccine industry in 2024.
Analysis report China's human rabies vaccine industry in 2024.
Analysis report China's human rabies vaccine industry in 2024.
Analysis report China's human rabies vaccine industry in 2024.

Analysis report China's human rabies vaccine industry in 2024.

€1.345,95
/
Tax included. Shipping calculated at checkout.
This study, "Analysis of China's Human Rabies Vaccine Industry: Supply, Demand, Competition, and Investment Prospects," offers a thorough examination of the market. It covers historical context, current demand and supply, competitive landscape, and investment opportunities. Key sections include a SWOT analysis, technological innovations, regulatory impacts, and cost structures. The report also highlights government policies and provides case studies for best practices. Ideal for investors, companies, and policymakers, this study provides crucial insights for navigating China's evolving human rabies vaccine industry.

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Study Overview

To help industry professionals and investors gain a deeper understanding of the current state and future prospects of the human rabies vaccine industry in China, Chinacuity and its partner in China have published the report titled "2025-2031 China Human Rabies Vaccine Market Panorama Survey and Development Trend Assessment" (hereafter referred to as "the report"). This document provides an in-depth analysis of the Chinese rabies vaccine market, based on years of tracking, field visits, surveys, and analysis conducted by Chinacuity and its partner.
To ensure data accuracy and the informative value of the content, the Chinacuity research team collected information from various sources, including annual reports of listed companies, manufacturer surveys, distributor discussions, and expert validation. The data were then analyzed from multiple dimensions to provide a comprehensive understanding of the development trends in 2023, ongoing innovations, and key challenges in the industry.


Overview of the Rabies Vaccine Industry

Rabies, also known as hydrophobia, is a severe viral disease caused by the rabies virus, with a mortality rate near 100%. It is a zoonotic disease primarily transmitted by animals. In China, the rabies vaccine is classified as a second-category vaccine and is the only means for controlling and preventing the disease. Human rabies vaccines are mainly intended for individuals at risk of infection and can be divided into four main types: Vero cell purified vaccines, hamster kidney cell-based vaccines, chicken embryo cell-based vaccines, and human diploid cell purified vaccines.


Market Fluctuations and Trends

Since 2017, the human rabies vaccine industry in China has experienced fluctuations in the number of market approvals. Following the Changsheng incident in 2018, vaccine approval quantities dropped significantly, reaching approximately 50 million doses. However, after the update of the "Pharmacopoeia of the People's Republic of China" in 2020, volumes quickly rebounded to around 80 million doses, showing signs of stabilization in recent years. In 2022, the number of approved doses reached 80.45 million, across 909 batches. Sales of rabies vaccines reached 68.94 million doses, with an average price of 75.1 RMB (approximately 10.3 USD) per dose.


Dominant Production Technology

The technology for culturing the rabies virus using Vero cells remains the primary method for rabies vaccine production in China due to its advantages in quality control, large-scale production, reduced contamination risk, and relatively low production costs. As a result, vaccines using this technology dominate the market, with companies such as Chengda Bio, Ningbo Rong'an, and Guangzhou Nuocheng being key producers. In contrast, human diploid cell-based vaccines have a smaller market share due to the complexity of large-scale bioreactor culture.


Case Study: Kanghua Bio

Kanghua Bio is a key player in this field, with products including the lyophilized human diploid cell rabies vaccine and the ACYW135 polysaccharide meningococcal vaccine. The lyophilized rabies vaccine is the first of its kind to be marketed in China, employing advanced large-scale bioreactor culture technology to ensure high safety, effective immunogenicity, and extended protection. In 2022, Kanghua Bio's revenue from rabies vaccines reached 1.424 billion RMB (approximately 195.4 million USD).


Outlook and Development Strategies (2025-2031)

In the future, Vero cells are expected to continue to be the main medium for culturing the rabies virus. Their inherent characteristics allow manufacturers to improve both quality and quantity in production. Additionally, some advanced companies are already adopting innovative techniques and production processes, enhancing vaccine quality while increasing production stability and control. Continued technological development, combined with streamlined mass production, is expected to support the modernization of the pharmaceutical industry in China.

Chapter 1 Overview of the Human Rabies Vaccine Industry


1.1 Definition and Characteristics of the Human Rabies Vaccine Industry


1.1.1 Definition and Classification of the Human Rabies Vaccine Industry
1.1.2 Analysis of Industry Characteristics

1.2 Analysis of Business Models in the Human Rabies Vaccine Industry

1.2.1 Analysis of Procurement Models
1.2.2 Analysis of Production Models
1.2.3 Analysis of Sales Models
1.2.4 Analysis of Factors Influencing Business Models in the Industry

1.3 Overview of Research in the Human Rabies Vaccine Industry


1.3.1 Research Objectives in the Industry
1.3.2 Principles of Industry Research
1.3.3 Research Methods in the Industry
1.3.4 Content of Industry Research

Chapter 2 Analysis of the Operating Environment of the Human Rabies Vaccine Industry in 2023


2.1 Analysis of the Political and Legal Environment in the Industry


2.1.1 Industry Regulatory System
2.1.2 Relevant Industry Standards
2.1.3 Relevant Development Policies in the Industry

2.2 Analysis of the Economic Environment in the Industry


2.2.1 Analysis of the Global Macroeconomy
2.2.2 GDP Analysis of the National Economy
2.2.3 Consumer Price Index (CPI) and Producer Price Index (PPI)
2.2.4 National Household Income Analysis
2.2.5 Engel Coefficient
2.2.6 Industrial Development Trends
2.2.7 Fixed Asset Investment Situation
2.2.8 Analysis of the Impact of the Economic Environment on the Industry

2.3 Analysis of the Social Environment in the Human Rabies Vaccine Industry


2.3.1 Social Environment of the Industry
2.3.2 Impact of the Social Environment on the Industry

2.4 Analysis of the Technological Environment in the Industry


2.4.1 Technological Analysis of Human Rabies Vaccines
2.4.2 Impact of the Technological Environment on the Industry

Chapter 3 Operational Trends in China's Pharmaceutical, Medical, and Related Industries in 2023


3.1 Analysis of the Pharmaceutical Industry Chain


3.2 Analysis of the Operations in the Pharmaceutical Industry


3.3 Analysis of the Development Status of the Biopharmaceutical Industry


3.4 Analysis of the Development Status of the Traditional Chinese Medicine Industry


3.5 Analysis of the Development Status of the Chemical Pharmaceutical Industry


3.6 Pharmaceutical Equipment


3.6.1 Main Product Types and Supply Analysis
3.6.2 Analysis of Development History
3.6.3 Analysis of Industry Operations

3.7 Overview of the Pharmaceutical Distribution Industry


3.7.1 Development Overview of the Pharmaceutical Distribution Industry
3.7.2 Overall Scale of the Industry
3.7.3 Profitability of Enterprises in the Industry
3.7.4 Ownership Structure of Enterprises in the Industry
3.7.5 Analysis of Seven Major Categories in the Industry

3.8 Overall Development Status of China's Pharmaceutical Terminal Market


3.8.1 Market Size
3.8.2 Market Structure
3.8.3 Analysis of Market Segments

3.9 Development of Medical Institutions and Demand for Medications


3.9.1 Overview of China's Healthcare Industry
3.9.2 Resources in the Healthcare Sector
3.9.3 Analysis of Services and Operations in Healthcare Institutions

3.10 Scale and Development Trends of Retail Pharmacies


3.10.1 Number and Market Size of Retail Pharmacies
3.10.2 Number and Market Size of Chain Pharmacies
3.10.3 Analysis of Pharmacy Business Indicators

Chapter 4 Analysis of the Human Rabies Vaccine Industry in China in 2023


4.1 Review of the Development History of the Industry


4.2 Market Supply Situation in the Industry
4.2.1 Domestic Production from 2018 to 2023
4.2.2 Domestic Manufacturers and Approvals
4.2.3 Distribution of Approvals by Region
4.2.4 Number of Manufacturers by Province

4.3 Market Demand in the Human Rabies Vaccine Industry


4.3.1 Domestic Demand Analysis from 2018 to 2023
4.3.2 Product Price Analysis
4.3.3 Factors Influencing Product Prices

4.4 Analysis of R&D Progress in the Industry

Chapter 5 Economic Indicators in China's Pharmaceutical Manufacturing Industry in 2023


5.1 Overview from 2018 to 2023


5.1.1 Analysis of the Number of Enterprises
5.1.2 Analysis of Total Assets
5.1.3 Analysis of Total Liabilities
5.1.4 Analysis of Sales Revenue
5.1.5 Analysis of Total Profits

5.2 Analysis of Supply in the Industry from 2018 to 2023


5.2.1 Total Output Value Analysis
5.2.2 Analysis of Finished Products

5.3 Analysis of Sales in the Industry from 2018 to 2023


5.3.1 Sales Output Value Analysis
5.3.2 Production-Sales Ratio Analysis

5.4 Analysis of Business Efficiency in the Industry


5.4.1 Analysis of Profitability
5.4.2 Analysis of Operational Efficiency
5.4.3 Analysis of Solvency
5.4.4 Analysis of Growth Potential

Chapter 6 Regional Development Analysis of the Human Rabies Vaccine Industry in China in 2023


6.1 Current Regional Development Status


6.2 Northern China from 2018 to 2023


6.2.1 Analysis of Regional Economic Development
6.2.2 Analysis of the Regional Industry Scale
6.2.3 Analysis of Regional Market Demand Potential

6.3 Northeast China from 2018 to 2023


6.3.1 Analysis of Regional Economic Development
6.3.2 Analysis of the Regional Industry Scale
6.3.3 Analysis of Regional Market Demand Potential

6.4 Eastern China from 2018 to 2023


6.4.1 Analysis of Regional Economic Development
6.4.2 Analysis of the Regional Industry Scale
6.4.3 Analysis of Regional Market Demand Potential

6.5 Central China from 2018 to 2023


6.5.1 Analysis of Regional Economic Development
6.5.2 Market Size Analysis
6.5.3 Industry Development Forecast

6.6 Southern China from 2018 to 2023


6.6.1 Analysis of Regional Economic Development
6.6.2 Market Size Analysis
6.6.3 Industry Development Forecast

6.7 Southwest China from 2018 to 2023


6.7.1 Analysis of Regional Economic Development
6.7.2 Analysis of the Regional Industry Scale
6.7.3 Analysis of Regional Market Demand Potential

6.8 Northwest China from 2018 to 2023


6.8.1 Analysis of Regional Economic Development
6.8.2 Analysis of the Regional Industry Scale
6.8.3 Analysis of Regional Market Demand Potential

Chapter 7 Competitiveness Analysis of Domestic Human Rabies Vaccine Manufacturers in 2023


7.1 Chengdu Kanghua Biological Products Co., Ltd.


7.1.1 Basic Development Information
7.1.2 Analysis of Main Products
7.1.3 Business Performance Analysis
7.1.4 Competitive Advantages Analysis

7.2 Liaoning Chengda Biological Co., Ltd.


7.2.1 Basic Development Information
7.2.2 Analysis of Main Products
7.2.3 Business Performance Analysis
7.2.4 Competitive Advantages Analysis

7.3 Changchun Zhuyi Biological Co., Ltd.


7.3.1 Basic Development Information
7.3.2 Analysis of Main Products
7.3.3 Business Performance Analysis
7.3.4 Competitive Advantages Analysis

7.4 Hualan Biological Vaccine Co., Ltd.


7.4.1 Basic Development Information
7.4.2 Analysis of Main Products
7.4.3 Business Performance Analysis
7.4.4 Competitive Advantages Analysis

7.5 Jilin Yatai Biological Pharmaceuticals Co., Ltd.


7.5.1 Basic Development Information
7.5.2 Analysis of Main Products
7.5.3 Business Performance Analysis
7.5.4 Competitive Advantages Analysis

Chapter 8 Competitive Landscape Analysis of the Human Rabies Vaccine Industry in 2023


8.1 Competitive Landscape of the Industry


8.1.1 Brand Competition Landscape
8.1.2 Analysis of Regional Concentration

8.2 Five Forces Analysis of the Industry


8.2.1 Competition Among Existing Firms
8.2.2 Analysis of Potential Entrants
8.2.3 Threat of Substitutes
8.2.4 Bargaining Power of Suppliers
8.2.5 Bargaining Power of Customers

8.3 Analysis of Industry Barriers


8.3.1 Talent Barriers
8.3.2 Business Barriers
8.3.3 Brand Barriers

8.4 Strategies for Enhancing Competitiveness from 2025 to 2031

Chapter 9 Investment Opportunities and Risks in the Human Rabies Vaccine Industry from 2025 to 2031


9.1 Investment Analysis in 2023


9.1.1 Overall Investment Structure in the Industry
9.1.2 Investment Scale Analysis
9.1.3 Regional Investment Analysis

9.2 Major Factors Influencing the Industry's Development


9.2.1 Favorable Factors for Industry Development
9.2.2 Unfavorable Factors for Industry Development
9.2.3 Challenges Faced by the Industry
9.2.4 Opportunities for Industry Development

9.3 Analysis of Investment Risks and Control Strategies


9.3.1 Market Risk and Control Strategies
9.3.2 Policy Risk and Control Strategies
9.3.3 Business Risk and Control Strategies
9.3.4 Technological Risk and Control Strategies
9.3.5 Risk of Competition in the Same Industry
9.3.6 Other Risks and Control Strategies

Chapter 10 Forecast of the Human Rabies Vaccine Industry Development Potential in China from 2025 to 2031


10.1 Supply Forecast from 2025 to 2031


10.2 Demand Forecast from 2025 to 2031


10.3 Analysis of Development Trends


10.4 Outlook for the Industry


10.5 Analysis of Regional Market Potential

Chapter 11 Investment Strategy Research and Recommendations for the Industry from 2025 to 2031


11.1 Development Strategy Research


11.2 Key Customer Strategy


11.3 Investment Strategy in the Industry


11.4 Development Recommendations

Contact Us for the Most Recent Versions of Our Studies

Thank you for your interest in our market research at Chinacuity. We are dedicated to providing you with quality insights to inform your decisions. Our catalog includes over a hundred studies, some of which are not yet in their final version or up to date.

We therefore invite you to contact us before any purchase to confirm availability and the most recent version of the desired study. For any questions or to place an order, do not hesitate to contact us at: contact@chinacuity.com. We are here to assist you.

Chinacuity leader in market research on China

Chinacuity's primary strength lies in its unrivaled local expertise. With teams established directly in China, Chinacuity benefits from privileged access to first-hand information. This direct immersion in the Chinese context gives the company a nuanced understanding of regional specificities, market trends, and local consumer behavior. By integrating this local knowledge with macroeconomic analysis, Chinacuity offers its clients a unique perspective, which goes beyond conventional data. This approach provides a more complete and precise understanding of the Chinese market, essential for companies seeking to establish or expand effectively in this dynamic region.

About us

You may also like

Recently viewed

Back to Medical

FAQs

Our data is collected by a dedicated team based in China, which conducts field surveys to ensure the relevance and timeliness of our information. This approach allows us to provide precise and high-quality insights to our clients.

Absolutely. To help you assess the quality and relevance of our studies, we offer a free preview that you can download. This preview document will give you a good overview of the structure and content of our full reports.

Once your purchase is complete, a download link will be immediately sent to you by email. This link will allow you direct access to the market study in PDF format. You can then download the document and begin using it for your analytical needs.

We are committed to providing high-quality market studies. However, once the study is downloaded, we are unable to offer a refund. We encourage you to use the free preview to ensure the study meets your expectations before purchase.